

RECEIVED
CENTRAL FAX CENTER

JUN 01 2006



GlaxoSmithKline

FAX

To Attn: Examiner B. Robinson , Group 1625
.....
Company USPTO
.....
Fax (571) 273-8300
.....
From Patty Wilson
.....
Tel 1-919-483-1007; Facsimile: 1-919-483-7977
.....
E-mail patricia.t.wilson@gsk.com
.....
Date June 1, 2006 Pages including cover 17
.....
Subject Application of: Beswick et al.
U.S. Serial No.: 10/518,778
Attorney Docket No. PG4814USw
.....

GlaxoSmithKline
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709

Tel: 919 483 2100
www.gsk.com

Attached: Response to Restriction Requirement (16 pgs).

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this correspondence is being facsimile
transmitted on June 1, 2006.

A handwritten signature in cursive script, appearing to read "Patty Wilson", written over a horizontal line.
Patty Wilson

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

PG4814USw

JUN 01 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Beswick et al.

Serial No.: 10/518,778

Examiner: B. Robinson

Filing Date: December 17, 2004

Art Unit: 1625

For: *Propionic acid Derivatives and Their Use as hPPAR Activators*

Commissioner for Patents

Washington D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This paper is submitted in response to the Office Action mailed March 1, 2006. Entry of the subject amendment, and reconsideration of the subject application is respectfully requested.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 9 of this paper.